Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Ulrik Lassen"'
Autor:
Primo N. Lara, M. Phillip DeYoung, Xiaowei Wang, Sergey Orlov, Enriqueta Felip, James Vasquez, Katherine Baker-Neblett, Manuel Domine, Nina Karaseva, Ulrik Lassen, Li Yan, Daniel Morgensztern, Pilar Garrido, Jose Manuel Trigo, Paul K. Paik, Marina Shomova, Ionel Mitrica, Ignacio Delgado, Olga Burdaeva
Publikováno v:
Lung Cancer. 136:74-79
Objectives GSK3052230 (FP-1039) is a soluble fusion protein that acts as ligand trap sequestering fibroblast growth factors (FGFs) involved in tumor growth and angiogenesis, while sparing the hormonal FGFs. Because of this selectivity, the molecule i
Autor:
Rebecca Kristeleit, Antoine Italiano, Hendrik Tobias Arkenau, Mika Mustonen, Pasi Hakulinen, Analia Azaro, Giuseppe Curigliano, Petri Bono, Jordi Rodon, Tarja Ikonen, Ulrik Lassen, Chris Garratt, Christophe Massard, Katriina Peltola
Publikováno v:
Scientia
ESMO Open, Vol 5, Iss 6 (2020)
ESMO Open
Bono, P, Massard, C, Peltola, K J, Azaro, A, Italiano, A, Kristeleit, R S, Curigliano, G, Lassen, U, Arkenau, H T, Hakulinen, P, Garratt, C, Ikonen, T, Mustonen, M V J & Rodon, J A 2020, ' Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours ', ESMO Open, vol. 5, no. 6, e001081 . https://doi.org/10.1136/esmoopen-2020-001081
ESMO Open, Vol 5, Iss 6 (2020)
ESMO Open
Bono, P, Massard, C, Peltola, K J, Azaro, A, Italiano, A, Kristeleit, R S, Curigliano, G, Lassen, U, Arkenau, H T, Hakulinen, P, Garratt, C, Ikonen, T, Mustonen, M V J & Rodon, J A 2020, ' Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours ', ESMO Open, vol. 5, no. 6, e001081 . https://doi.org/10.1136/esmoopen-2020-001081
Estudi d'escalada de dosis; Fase I; Tumors sòlids Estudio de escalada de dosis; Fase I; Tumores sólidos Dose escalation study; Phase I; Solid tumours Background Genetic alterations in fibroblast growth factor receptor (FGFR) and vascular endothelia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::164c723e495210e45a1eff22d3221919
https://hdl.handle.net/11351/6423
https://hdl.handle.net/11351/6423
Publikováno v:
BBA Clinical
Østrup, O, Ahlborn, L B, Lassen, U, Mau-Sørensen, M & Nielsen, F C 2017, ' Detection of copy number alterations in cell-free tumor DNA from plasma ', BBA Clinical, vol. 7, pp. 120-126 . https://doi.org/10.1016/j.bbacli.2017.03.006
Østrup, O, Ahlborn, L B, Lassen, U, Mau-Sørensen, M & Nielsen, F C 2017, ' Detection of copy number alterations in cell-free tumor DNA from plasma ', BBA Clinical, vol. 7, pp. 120-126 . https://doi.org/10.1016/j.bbacli.2017.03.006
Background Somatic copy number alterations (SCNAs) occurring in tumors can provide information about tumor classification, patient's outcome or treatment targets. Liquid biopsies, incl. plasma samples containing circulating cell-free tumor DNA (ccfDN
Autor:
Max Hasmann, J.M. Cejalvo, Maria Martinez Garcia, Alejandro Navarro Mendivil, Andrés Cervantes, Morten Mau-Soerensen, Tania Fleitas Kanonnikoff, Martin Weisser, Ulrik Lassen, Natasha B. Leighl, Ian James, Francesca Michielin, Celine Adessi, Wolfgang Jacob, Maurizio Ceppi, Enriqueta Felip, Alvaro Taus Garcia
Publikováno v:
ESMO Open
ESMO Open, Vol 4, Iss 4 (2019)
Cejalvo, J M, Jacob, W, Fleitas Kanonnikoff, T, Felip, E, Navarro Mendivil, A, Martinez Garcia, M, Taus Garcia, A, Leighl, N, Lassen, U, Mau-Soerensen, M, Adessi, C, Michielin, F, James, I, Ceppi, M, Hasmann, M, Weisser, M & Cervantes, A 2019, ' A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer ', ESMO Open, vol. 4, no. 4, e000532 . https://doi.org/10.1136/esmoopen-2019-000532
ESMO Open, Vol 4, Iss 4 (2019)
Cejalvo, J M, Jacob, W, Fleitas Kanonnikoff, T, Felip, E, Navarro Mendivil, A, Martinez Garcia, M, Taus Garcia, A, Leighl, N, Lassen, U, Mau-Soerensen, M, Adessi, C, Michielin, F, James, I, Ceppi, M, Hasmann, M, Weisser, M & Cervantes, A 2019, ' A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer ', ESMO Open, vol. 4, no. 4, e000532 . https://doi.org/10.1136/esmoopen-2019-000532
Purpose This study investigated the safety and clinical activity of lumretuzumab, a humanised antihuman epidermal growth factor receptor 3 (HER3) monoclonal antibody, in combination with carboplatin and paclitaxel in first-line treatment of patients
Autor:
Jane Skjøth-Rasmussen, Wiktor Majewski, Marie-Thérése Stockhausen, Helle Broholm, Mette Villingshøj, Jannick Brennum, Petra Hamerlik, Mikkel Staberg, Hans Skovgaard Poulsen, Thomas Urup, Christopher Meulengracht, Andreas Kjaer, Kamilla E. Jensen, Ulrik Lassen, Signe Regner Michaelsen, Slavka Lukacova, Henriette Pedersen, Mette K. Nedergaard
Publikováno v:
Michaelsen, S R, Staberg, M, Pedersen, H, Jensen, K E, Majewski, W, Broholm, H, Nedergaard, M K, Meulengracht, C, Urup, T, Villingshøj, M, Lukacova, S, Skjøth-Rasmussen, J, Brennum, J, Kjær, A, Lassen, U, Stockhausen, M-T, Poulsen, H S & Hamerlik, P 2018, ' VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance ', Neuro-Oncology, vol. 20, no. 11, pp. 1462-1474 . https://doi.org/10.1093/neuonc/noy103
Background Glioblastoma ranks among the most lethal cancers, with current therapies offering only palliation. Paracrine vascular endothelial growth factor (VEGF) signaling has been targeted using anti-angiogenic agents, whereas autocrine VEGF/VEGF re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e2fb9210d890c257f5fae529610986c
https://pure.au.dk/portal/da/publications/vegfc-sustains-vegfr2-activation-under-bevacizumab-therapy-and-promotes-glioblastoma-maintenance(5c36a0f9-e363-4cdf-bc04-d8708e72efae).html
https://pure.au.dk/portal/da/publications/vegfc-sustains-vegfr2-activation-under-bevacizumab-therapy-and-promotes-glioblastoma-maintenance(5c36a0f9-e363-4cdf-bc04-d8708e72efae).html
Autor:
Camilla Klausen, Kenneth Francis Hofland, Morten Mau-Sørensen, Ulrik Lassen, Per Cayé-Thomasen, Mikkel Christian Alanin, Kaare Fugleholm, Lars Poulsgaard, Carsten Thomsen
Publikováno v:
International Journal of Neuroscience. 126:1002-1006
The hallmark of neurofibromatosis type 2 (NF2) is bilateral vestibular schwannomas (VS). Approximately 80% of NF2 patients also have intracranial meningiomas. Vascular endothelial growth factor (VEGF) is expressed in both NF2-related and sporadic occ
Autor:
Andrés Cervantes, Maria Martinez-Garcia, Florence Joly, Georgina Meneses-Lorente, Maurizio Ceppi, Joan Albanell, Christelle Levy, Christoph Schindler, Iria Gonzalez, Véronique Diéras, Francesca Michielin, Annie Moisan, Celine Adessi, Martin Weisser, Wolfgang Jacob, Andreas Schneeweiss, Jose A. Lopez-Martin, Tomas Racek, Ulrik Lassen, Javier Cortes, Ian James, Max Hasmann, Tjoung-Won Park-Simon, Anja Welt, Marcus May, Frederik Marmé, Juan Miguel Cejalvo
Publikováno v:
INVESTIGATIONAL NEW DRUGS
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Schneeweiss, A, Park-Simon, T W, Albanell, J, Lassen, U, Cortés, J, Dieras, V, May, M, Schindler, C, Marmé, F, Cejalvo, J M, Martinez-Garcia, M, Gonzalez, I, Lopez-Martin, J, Welt, A, Levy, C, Joly, F, Michielin, F, Jacob, W, Adessi, C, Moisan, A, Meneses-Lorente, G, Racek, T, James, I, Ceppi, M, Hasmann, M, Weisser, M & Cervantes, A 2018, ' Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer ', Investigational New Drugs, vol. 36, no. 5, pp. 848-859 . https://doi.org/10.1007/s10637-018-0562-4
Investigational New Drugs
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Schneeweiss, A, Park-Simon, T W, Albanell, J, Lassen, U, Cortés, J, Dieras, V, May, M, Schindler, C, Marmé, F, Cejalvo, J M, Martinez-Garcia, M, Gonzalez, I, Lopez-Martin, J, Welt, A, Levy, C, Joly, F, Michielin, F, Jacob, W, Adessi, C, Moisan, A, Meneses-Lorente, G, Racek, T, James, I, Ceppi, M, Hasmann, M, Weisser, M & Cervantes, A 2018, ' Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer ', Investigational New Drugs, vol. 36, no. 5, pp. 848-859 . https://doi.org/10.1007/s10637-018-0562-4
Investigational New Drugs
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Summary Purpose To investigate the safety and clinical activity of comprehensive human epidermal growth factor receptor (HER) family receptor inhibition using lumretuzumab (anti-HER3) and pertuzumab (anti-HER2) in combination with paclitaxel in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0126ade335d0c5340693a09cb65b79e
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2445
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2445
Autor:
Jordi Bertran-Alamillo, Carles Codony-Servat, Mónica Garzón, Rafael Rosell, Martin R. Larsen, Ana Giménez-Capitán, Niki Karachaliou, Trever G. Bivona, Jordi Codony-Servat, Martin Haar Pedersen, Cristina Teixidó, Enriqueta Felip, Santiago Viteri, Josep Castellví, Ana Drozdowskyj, Ulrik Lassen, Kirstine Jacobsen, Henrik J. Ditzel, Miguel Angel Molina
Publikováno v:
Nature Communications
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Nature communications, vol 8, iss 1
Nature Communications, Vol 8, Iss 1, Pp 1-14 (2017)
Jacobsen, K, Bertran-Alamillo, J, Molina, M A, Teixidó, C, Karachaliou, N, Pedersen, M H, Castellví, J, Garzón, M, Codony-Servat, C, Codony-Servat, J, Giménez-Capitán, A, Drozdowskyj, A, Viteri, S, Larsen, M R, Lassen, U, Felip, E, Bivona, T G, Ditzel, H J & Rosell, R 2017, ' Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer ', Nature Communications, vol. 8, 410 . https://doi.org/10.1038/s41467-017-00450-6
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Nature communications, vol 8, iss 1
Nature Communications, Vol 8, Iss 1, Pp 1-14 (2017)
Jacobsen, K, Bertran-Alamillo, J, Molina, M A, Teixidó, C, Karachaliou, N, Pedersen, M H, Castellví, J, Garzón, M, Codony-Servat, C, Codony-Servat, J, Giménez-Capitán, A, Drozdowskyj, A, Viteri, S, Larsen, M R, Lassen, U, Felip, E, Bivona, T G, Ditzel, H J & Rosell, R 2017, ' Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer ', Nature Communications, vol. 8, 410 . https://doi.org/10.1038/s41467-017-00450-6
Non-small-cell lung cancer patients with activating epidermal growth factor receptor (EGFR) mutations typically benefit from EGFR tyrosine kinase inhibitor treatment. However, virtually all patients succumb to acquired EGFR tyrosine kinase inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3971a73a7b874cb853f9f4c3c3e65794
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6106
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6106
Autor:
Lise Barlebo Ahlborn, Mette Madsen, Christina Westmose Yde, Finn Cilius Nielsen, Morten Mau-Sørensen, Lars Jønson, Ulrik Lassen
Publikováno v:
Clinical Laboratory. 63
Background Small fragments of tumor DNA can be found in the circulation of cancer patients, providing a noninvasive access to tumor material (liquid biopsy). Analysis of circulating tumor DNA (ctDNA) has been used for diagnosis, treatment decisions,
Autor:
Cécile Gouttefangeas, Christian H. Ottensmeier, Hans Skovgaard Poulsen, Norbert Hilf, Valesca Bukur, Ulrik Lassen, Berta Ponsati, Judith R. Kroep, P thor Straten, Jordi Rodon, Michael Platten, Ugur Sahin, H Okada, Ghazaleh Tabatabai, Pierre-Yves Dietrich, Stefan Stevanovic, Arie Admon, Wolfgang Wick, Harpreet Singh-Jasuja, A. von Deimling, Francisco Martínez-Ricarte, H.-G. Rammensee, Katrin Frenzel, S.H. van der Burg
Publikováno v:
Neuro-Oncology. 20:iii219-iii219
BACKGROUND: There is a need for treatment personalization as every cancer is molecularly unique. In addition glioblastoma (GB) are immunologically regarded as resistant, “cold” tumor with few targetable antigens available from mutations, thus dem